Understanding mechanisms by which glibenclamide stimulates insulin release is important particularly given recent promising treatment by glibenclamide of permanent neonatal diabetic subjects. Anti-diabetic sulfonylureas are thought to stimulate insulin secretion solely by inhibiting their high affinity K ATP channel receptors at the plasma membrane of cells. This normally occurs during glucose stimulation where ATP inhibition of plasmalemmal K ATP channels leads to voltage-activation of L-type calcium channels for rapidly switching on and off calcium influx governing the duration of insulin secretion. However, growing evidence indicates that sulfonylureas including glibenclamide have additional K ATP channel receptors within cells at insulin granules.
INTRODUCTION
To understand the mechanisms underlying insulin secretion by glibenclamide, its functional sites of action in the cell of the endocrine pancreas must be identified. The plasmalemmal K ATP channel site for glibenclamide stimulated insulin release is well studied (3) . In glucose stimulated insulin secretion (GSIS), the plasmalemmal K ATP channel transduces the signal of elevated glucose metabolism into calcium influx across the plasmalemma. The calcium then completes the final exocytic step by fusing previously primed insulin granules to the plasmalemma, experimentally observed as a transient first phase insulin release (36) .
Generally, K ATP channels couple glucose metabolism and membrane electrical signaling (1, 2, 10, 16, 27) . K ATP channels are ideal receptors for ligands signaling changes in glucose metabolism as they are designed as sensors of adenine nucleotide levels. ATP binding to the K ir 6.2 subunit of the K ATP channel inhibits the potassium efflux that otherwise maintains the electrically negative resting state of the cell. ADP binding to the SUR1 subunit of the K ATP channel can antagonize the inhibition gating and restore the resting state. Thus, the inhibition gating by ATP, and its antagonism by ADP, allow glucose metabolism to tightly regulate the cell plasmalemmal potential allowing L-type calcium channels and calcium influx to be rapidly switched on or off. This calciumcontrolled signaling pathway initiating GSIS is the cell's initial but transient response to curb rises in blood glucose levels.
A prolonged duration of high blood glucose levels, however, requires sustained insulin secretion. Experimentally, this sustained regulatory phase is observed as second phase insulin release (36) . Relatively little is known about the mechanisms coupling rates of high glucose metabolism to the second phase, even though second phase is disrupted in most forms of diabetes. What is known is that calcium plays different roles in second phase than it does in first phase insulin secretion (36, 19, 40) . In response to glucose stimulation, first phase release is initiated by a rise in calcium but is terminated by rapid depletion of a limited supply of Ca 2+ -releasable secretory granules at the plasmalemma.
Importantly, the calcium level remains elevated and, after a characteristic delay, a second signal from high glucose metabolism stimulates the re-supply of the Ca 2+ -releasable secretory granule pool at the plasmalemma. As for first phase, ATP and ADP are candidate signals coupling high glucose metabolism and second phase secretion (11, 14, 20, 38) , but their receptor proteins in the cell are unknown.
Plasmalemmal K ATP channels are unlikely candidate receptors by which glucose stimulates second phase. If another signaling pathway is used to elevate intracellular calcium, for example raising extracellular KCl from 4.8 to 30 mM, then second phase insulin secretion becomes plasmalemmal K ATP channel-independent (19, 20, 40) . Under these conditions high glucose stimulates further increases in insulin release without further increasing intracellular calcium (36) . These studies raise the question whether additional K ATP channels other than plasmalemmal K ATP channels couple glucose metabolism to the re-supply of Ca 2+ -releasable secretory granules for sustained second phase release.
Glibenclamide also appears to have binding sites within the cell, in addition to its plasmalemmal K ATP channel sites. Glibenclamide is distinguished from other anti-diabetic sulfonylureas, not only by its superior secretagogue potency, but also by its exceptional ability to be internalized within cells (23, 25, 26) . Furthermore, glibenclamide has been shown to localize to high affinity sites of the insulin secretory granule membrane (7,34), which recently have been identified as K ATP channel subunits (21, 47, 50 In this study, we determined whether glibenclamide, which mimics ATP inhibition of K ATP channels, has an effect on insulin secretion independent of plasmalemmal K ATP channels. To bypass the signaling pathway involving the plasmalemmal K ATP channel, we applied high potassium depolarization of the cell plasmalemma, which activates the L-type channels, and monitored cell calcium by either rhod-2 (12) or GCamP2 fluorescent indicators (46) . Insulin release was assayed by both dynamic perifusion and live-cell imaging of fluorescently labeled insulin. The results show that in the presence of high potassium depolarization, glibenclamide stimulates a sustained insulin secretion without further increasing calcium.
MATERIALS AND METHODS
Islet preparation and culture. Murine islets were isolated from male BALB/c mice (20-25 g; Taconic, Germantown, NY). Islets were isolated by intraductal collagenase injection, as previously described (6), and cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 7.5 mM glucose, 100 Hg/ml streptomycin, 100 units/ml penicillin, 2 mM L-glutamine (Life Technologies, Grand Island, NY), in a humidified 5% CO 2 incubator at 37ºC. Confocal monitored release of Ins-C-GFP labeled insulin secretory granules.
Islet
Islets were infected with Ins-C-GFP and, within two days, assayed in KRRB at 37 0 C, as described (48) . Solution changes were performed by superfusion using the BioLogic little or no effect on the majority of cells.
The glibenclamide-stimulated release depends on calcium. as a divalent normally present in KRBB should suffice for maintenance of the cell membrane. Figure   7 shows the results of three experiments where glibenclamide-stimulated release failed to proceed without free calcium. Insulin secretion returned once free calcium was restored in the secretory buffer, indicating that the islets were competent for release.
Therefore, glibenclamide and high extracellular potassium are insufficient for insulin secretion in the absence of calcium.
DISCUSSION
Under conditions of sustained high potassium depolarization and elevated cell calcium, we found that glibenclamide stimulated a second phase release of insulin, which mimicked second phase release of insulin by high glucose. Insulin secretion and calcium levels were each measured in intact islet cells by distinct and direct methods.
Together with the identification of K ATP channels at insulin granules (21, 47, 50) show elevated cell calcium levels in low glucose (2.8 mM) yet in high glucose (16.7 mM) show neither changes in the high calcium levels nor significant GSIS (15, 32, 44) . In the knock-down model, in which K ir 6.2 expression was disrupted by hammerhead ribozymes, high glucose also failed to stimulate second phase insulin release despite chronically elevated calcium (31) . Another SUR1 knock-out model, however, in earlier studies showed islets with dramatically slowed insulin secretory responses to glucose regulation (42), whereas more recent results showed surprisingly normalized GSIS (33) .
In this model, either the K ATP channel is dispensable for normal GSIS or compensatory factors have come into play (33).
An intracellular role for sulfonylureas has been previously suggested based on in vitro results showing that intracellular injection of tolbutamide into whole-cell clamped cells increased its cell capacitance, as a measure of insulin secretion (4, 18) . Intracellular injection of ADP was also shown to block the cell capacitance increase. The results reported here extend these findings to intact islets and show glibenclamide-stimulated secretion associated with second phase measured directly by insulin assay. In the confocal measurements reported here, the overall decrease in membrane fluorescence observed indicates that any stimulated rate of granule cargo arrival at the membrane is less than the rates of the exocytic release and endocytic internalization. Together, the sustained stimulated secretory rate observed by insulin assay, together with the decrease in membrane cargo fluorescence, is consistent with a stimulated arrival rate but one that is more than offset by the other two departure rates. 
